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7101 Report (998 of 1000 words)102103 Neurotrophic keratitis/keratopathy (NK), a rare degenerative corneal disease, lacks 104 effective pharmacologic therapies.1 Because NK pathology involves trigeminal nerve 105 damage and loss of corneal innervation, nerve growth factor (NGF) is surmised to promote 106 healing of NK.2 Preliminary studies with murine NGF demonstrated efficacy for treating 107 corneal neurotrophic ulcers3; however, the complex tertiary structure of NGF has 108 complicated the production of recombinant human NGF (rhNGF) suitable for clinical 109 development. To this end, we developed an E. coli-derived rhNGF formulation that 110 demonstrated to be well tolerated and safe for topical ophthalmic use in a phase I study in 111 healthy volunteers.4 Here, we report phase I results of topical rhNGF for patients with 112 moderate-to-severe NK.113114 NGF0212/REPARO (Latin, “repair”) was a phase I/II randomized, double-masked, 115 multicenter, vehicle-controlled, parallel group study (ClinicalTrials.gov identifier 116 NCT01756456) that evaluated the safety and efficacy of rhNGF eye drops (10 or 20 µg/ml, 117 6 drops/day for 8 weeks) in patients with moderate (stage 2) or severe (stage 3) NK. 118119 Patients ≥18 years of age with stage 2/3 NK were enrolled according to published 120 diagnostic criteria and inclusion/exclusion criteria described in the REPARO phase II 121 report.5 Table 1 summarizes patient demographics, baseline characteristics, and prior NK 122 treatments.123
8124125 Eighteen patients (2 cohorts of 9 consecutively enrolled patients each) with stage 2 or 3 NK 126 gave informed consent and were randomized 7:2 to rhNGF 10 μg/ml vs. vehicle (cohort A) 127 or rhNGF 20 μg/ml vs. vehicle (cohort B). Sample size was based on clinical feasibility (i.e., 128 no formal power calculation was performed), as phase I aimed primarily to assess the 129 safety and systemic absorption of topical rhNGF to support proceeding with phase II, which 130 was conducted, analyzed, and reported separately.5 131132 Patients, investigators, and site/sponsor staff were masked to primary randomized 133 treatment. Indistinguishable treatment kits were randomly assigned by Statistical Analysis 134 System programmers. A clinical research organization maintained the masked database. No 135 formal statistical testing was applied to phase I data. The study obtained institutional 136 review board and independent ethics committee approval (detailed in the phase II report5) 137 and complied with the Declaration of Helsinki, Code of Federal Regulations, and Good 138 Laboratory/Clinical Practice guidelines.139140 Figure S1 (available at www.aaojournal.org) depicts overall study design and patient 141 disposition, including reasons for withdrawal. The study included an 8-week controlled 142 treatment period and a 48- or 56-week follow-up (duration determined by treatment 143 allocation and corneal healing status during controlled treatment). In the event of treatment 144 failure during the 8-week controlled treatment period (pre-defined as failure to achieve corneal 145 healing, recurrence of NK after healing, or deterioration as described in the phase II 146 report5), vehicle-treated patients were eligible to receive 8 weeks of uncontrolled rhNGF 
9147 treatment (cohort A: 10 µg/ml; cohort B: 20 µg/ml) before continuing follow-up (total 148 follow-up: 56 weeks). However, no phase I patients entered the 56-week follow-up period.149150 The primary safety variable was incidence of adverse events (AEs), defined per GCP 151 guidelines as any untoward medical occurrences in patients who received study treatment, 152 regardless of causal or temporal association. Other safety parameters included visual 153 analogue scale for ocular tolerability (described in the phase II report5), best corrected 154 distance visual acuity measured in Early Treatment Diabetic Retinopathy Study (ETDRS) 155 letters, intraocular pressure, dilated fundus ophthalmoscopy, vital signs, hematology, and 156 clinical chemistry. 157158 Table 1 summarizes treatment-related AEs (TAEs), defined as AEs recorded by the 159 investigator as having possible, probable, or highly probable relationships to study 160 treatment, during controlled treatment. Eye pain and headache were the most frequently 161 reported TAEs during controlled treatment, each occurring in 2 patients (28.6%) in the 162 rhNGF 20 μg/ml group. TAEs reported during controlled treatment occurred in 1 of 18 163 patients each. No TAEs were reported during the 48-week follow-up. No deaths occurred 164 controlled treatment or follow-up, nor were there any notable trends or clinically 165 significant differences over time or between treatment groups in laboratory parameters, 166 vital signs, or other ocular safety assessments.167168 Pharmacokinetics (PK) profiling was performed as described previously.4 As shown in 169 Figure S2 (available at www.aaojournal.org), only two patients had detectable serum NGF 
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170 at any time point. Of note, the patient in rhNGF 10 μg/ml group only had one positive NGF 171 measurement during the study, and the patient in the rhNGF 20 μg/ml group had 172 detectable serum NGF levels at all time points, even prior to initiating study treatment. 173 Taken together, the PK results suggest individual fluctuations of endogenous NGF 174 independent of study treatment. 175176 Although the phase I study was not designed or powered for efficacy outcomes, corneal 177 healing (<0.5 mm fluorescein staining in the lesion area) was assessed in clinical pictures 178 by central readers (masked to treatment assignment and duration) at week 4 (primary 179 endpoint) and week 8 (key secondary endpoint). At week 4, based on post-baseline last-180 observation-carried-forward analysis, corneal healing was achieved by 1/4 patients 181 (25.0%) receiving vehicle, 3/7 patients (42.9%) receiving rhNGF 10 μg/ml, and 3/7 182 patients (42.9%) receiving rhNGF 20 μg/ml. Of patients with responses available at week 8, 183 corneal healing was achieved by 1/2 patients (50%) receiving vehicle, 4/6 patients 184 (66.7%) receiving rhNGF 10 μg/ml, and 6/7 patients (85.7%) receiving rhNGF 20 μg/ml. 185 No phase I patients discontinued due to a lack of efficacy or inadequate control of NK. Prior 186 to week 8, no patients in any treatment group experienced deterioration. At week 8, 1 187 patient who received rhNGF 20 μg/ml experienced a decrease in BCDVA score of >5 ETDRS 188 letters.189190 The REPARO phase I study demonstrated that topical ophthalmic rhNGF (10 or 20 μg/ml), 191 administered 6 drops/day for 8 weeks, was well tolerated in patients with stage 2/3 NK. 192 No safety concerns arose; most AEs were ocular, mild, transient, and did not require 
11
193 discontinuing or corrective treatments. Most patients had undetectable serum NGF, and 194 systemic AEs were infrequent and mild. This is consistent with previous PK findings in 195 healthy volunteers4 and lack of detectable systemic NGF or immunogenicity in the phase II 196 study.5 Taken together, these results suggest unlikely systemic absorption or accumulation 197 of rhNGF. Favorable trends in corneal healing suggest that topical ophthalmic rhNGF may 198 be effective for treating patients with moderate-to-severe NK.
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1Table 1. Patient demographics, baseline characteristics, prior treatments, and treatment-
related adverse events* (controlled treatment period). 
Characteristics rhNGF 10 μg/ml(N=7)
rhNGF 20 μg/ml
(N=7)
Vehicle
(N=4)
Age (years)
Mean (SD) 61.7 (21.47) 52.0 (17.24) 64.3 (24.06)
Median (min, max) 67.0 (29, 80) 55.0 (24, 71) 68.5 (34, 86)
Female, n (%) 3 (42.9) 4 (57.1) 2 (50.0)
Ethnicity, n (%)
Hispanic, Latino, or Spanish 1 (14.3) 0 0
N/A 0 1 (14.3) 0
Race, n (%)
White 7 (100.0) 6 (85.7) 4 (100.0)
N/A 0 1 (14.3) 0
Primary NK diagnosis, n (%)
Stage 2 3 (42.9) 5 (71.4) 2 (50.0)
Stage 3 4 (57.1) 2 (28.6) 2 (50.0)
Underlying etiology, n (%)
Diabetes mellitus 1 (14.3) 2 (28.6) 1 (25.0)
Dry eye disease 1 (14.3) 0 0
Herpetic eye disease* 1 (14.3) 2 (28.6) 2 (50.0)
Neurosurgical procedure (medulloblastoma excision) 2 (28.6) 1 (14.3) 0
Ocular surgery or procedure
Cataract surgery/scleral buckle/vitrectomy 1 (14.3) 1 (14.3) 0
Keratoplasty 1 (14.3) 0 0
LASIK 0 1 (14.3) 0
Stroke 0 0 1 (25.0)
Prior treatments, n (%)†
Artificial tears/gels/ointments 1 (14.3) 6 (85.7) 3 (75.0)
Preservative free artificial tears/gels/ointments 4 (57.1) 4 (57.1) 2 (50.0)
Topical antibiotics 4 (57.1) 4 (57.1) 3 (75.0)
Therapeutic contact lens 2 (28.6) 1 (14.3) 1 (25.0)
Autologous serum eye drops 1 (14.3) 2 (28.6) 1 (25.0)
Other 0 2 (28.6) 0
Treatment-related Adverse Events N’ n N’ n N’ n
Body system
MedDRA preferred term
Any adverse event 4 1 (14.3) 12 3 (42.9) 1 1 (25.0)
Eye disorders 3 1 (14.3) 5 3 (42.9) 1 1 (25.0)
Eye pain 0 0 2 2 (28.6) 0 0
Conjunctival hyperemia 2 1 (14.3) 0 0 0 0
Erythema of eyelid 1 1 (14.3) 0 0 0 0
Eye inflammation 0 0 1 1 (14.3) 0 0
Eye irritation 0 0 1 1 (14.3) 0 0
Foreign body sensation in eyes 0 0 0 0 1 1 (25.0)
Photophobia 0 0 1 1 (14.3) 0 0
General disorders and administration site conditions 1 1 (14.3) 3 2 (28.6) 0 0
Disease progression‡ 1 1 (14.3) 0 0 0 0
Fatigue 0 0 1 1 (14.3) 0 0
Instillation site pruritus 0 0 1 1 (14.3) 0 0
Irritability 0 0 1 1 (14.3) 0 0
Nervous system disorders 0 0 2 2 (28.6) 0 0
2Headache 0 0 2 2 (28.6) 0 0
Cardiac disorders 0 0 1 1 (14.3) 0 0
Cardiovascular disorder§ 0 0 1 1 (14.3) 0 0
Musculoskeletal and connective tissue disorders 0 0 1 1 (14.3) 0 0
Muscle spasms 0 0 1 1 (14.3) 0 0
Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; min = minimum; max = maximum; N/A: not available 
(ethnicity and race were not collected in all countries); N = number of patients randomized to each treatment group at baseline; n 
= number of patients in each category; N’ = number of adverse events reported, n’ = number of patients reporting the adverse 
event; rhNGF = recombinant human nerve growth factor; SD = standard deviation.
Percentages (%) are calculated using the number randomized to each treatment group (N) as the denominator.
*Treatment-related adverse events are those events recorded by the investigator as having a possible, probable, or highly 
probable relationship to study treatment.
†Includes herpes simplex, herpes zoster, and recurrent herpetic keratitis
‡Patients may have received more than one prior treatment
§Disease progression was defined as increase in lesion size ≥ 1mm; decrease in best corrected distance visual acuity (BCDVA) 
by >5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; progression in lesion depth to corneal melting or 
perforation; or onset of infection. One patient in the rhNGF 10 μg/ml group had ≥ 1mm increase in lesion size from baseline.
One patient had a transient decrease in blood pressure from baseline
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Figure S1. REPARO Phase I study design and overall patient disposition. 
 
 
 
The REPARO phase I study evaluated the safety of topical ophthalmic recombinant human nerve growth factor 
(rhNGF), 6 drops daily for 8 weeks, in 18 patients (two cohorts of 9 consecutively enrolled patients) with 
neurotrophic keratitis of severity stage 2 (persistent epithelial defect) or stage 3 (corneal ulcer). Enrollment of 
cohort A (randomized 7:2 to 10 µg/ml rhNGF or vehicle) preceded enrollment of cohort B (randomized 7:2 to 20 
µg/ml rhNGF or vehicle). Patients received 8 weeks of controlled treatment and 48 weeks of follow-up. A 56-week 
follow-up period was intended for vehicle-treated patients who experienced treatment failure (see text for details), 
and was to include an additional 8 weeks of uncontrolled treatment with 10 µg/ml rhNGF (cohort A) or 20 µg/ml 
rhNGF (cohort B) before continuing follow-up for 48 weeks. No patients from the phase I study entered the 56-
week follow-up. 
Figure S2. REPARO Phase I Pharmacokinetics. 
Serum concentration of nerve growth factor (NGF) plotted over time for individual patients in 
the REPARO Phase I study. Blood samples were taken from patients receiving recombinant 
human NGF (rhNGF) or vehicle for pharmacokinetics (PK) profiling at various time points over 
the 8-week controlled treatment period (on days 1, 2; weeks 1, 2, 3, 4, 6; day 55; and week 8). 
Multiple time points (ranging from 0.5 hours pre-dose to 8 hours post-dose) were taken on days 
at the beginning and end of the controlled treatment period. For the purpose of these plots, 
measurements below the lower limit of quantification (LLQ) of 32.000 pg/ml were considered as 
0 pg/ml, and only patients with measurements >LLQ are shown. In the rhNGF 10 µg/ml group 
(n=7, ●), one patient had a serum NGF concentration of 130.868 pg/ml (0.5 hours post dose) on 
day 1, then <LLQ at all other time points tested. In the rhNGF 20 µg/ml group (n=7, ), one 
patient had serum NGF concentrations >LLQ at all time points, even prior to treatment initiation 
(893.53 pg/ml 0.5 hours pre-dose on day 1) and ranging from 247.7 pg/ml (week 1) to 
1010.7 pg/ml (week 3) during the 8-week controlled treatment period. In the vehicle group (n=4, 
not shown), no patients had detectable serum NGF at any time point tested. 
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